

**Important Note Regarding the September 11, 2017 Press Release Announcing Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma**

---

[This press release](#) has been corrected to address an error in the fourth sentence of the first paragraph. In the previous version, the mean improvement in lung function (FEV1) over placebo in mL was misstated in patients taking a 300 mg dose of dupilumab with 150 eosinophilic cells/microliter or greater. The correct mean improvement as assessed by FEV1 in these patients is 150 mL, not 210 mL as previously stated. Both versions correctly stated the corresponding percentage improvement (11 percent).

**Contacts Regeneron:****Media Relations****Ilana Tabak**

Tel: + 1 (914) 847-3836

Mobile: +1 (914) 450-6677

[ilana.tabak@regeneron.com](mailto:ilana.tabak@regeneron.com)**Investor Relations****Manisha Narasimhan, Ph.D.**

Tel: +1 (914) 847-5126

[Manisha.narasimhan@regeneron.com](mailto:Manisha.narasimhan@regeneron.com)

###